基本信息
浏览量:0
![](https://originalfileserver.aminer.cn/sys/aminer/icon/show-trajectory.png)
个人简介
I obtained my B.S. in Pharmacy at the Universidad de Navarra in June 1999. The following year I started my PhD studies in the Department of Neuropharmacology (Faculty of Medicine, Universidad de Navarra), funded by a predoctoral fellowship from the “Ramon Areces Foundation” obtaining the Ph.D in Neuropharmacology with the calification of “cum laude” (April 2004). I took postdoctoral training at the Neuroscience Department of the Center for Applied Medical Research (CIMA) for two years in Neurobiology of Alzheimer disease, while teaching Pharmacology in the Faculty of Medicine.
In 2007, I started to work as a Research Scientist in the group of Dr. Pérez-Otaño in CIMA, participating in many competitive national and international projects. I would like to point out my co-direction of the PhD of Partha Narayan Dey at the Universidad de Navarra (February 2017)
In 2017 I started working in the group of Adoptive Cell Therapy of the Hematology-Oncology program in CIMA, under the supervision of Dr. Felipe Prósper and Dr. Juan Roberto Rodríguez Madoz. During the first 2 years I participated in European and National projects focused on the use of cutting-edge technologies like genome editing and cell reprogramming. In addition to my experience in the experimental research tools previously refered, I obtained great knowledge in CRISPR/Cas9 technology for in vitro and in vivo gene editing. I was involved in the generation and characterization of patient-specific hIPSCs (human- induced pluripotent stem cells) from primary peripheral blood mononuclear cells (PBMCs) and primary fibroblasts as the first model based on cell reprogramming, and also performed protocols for differentiations of the generated hIPSCs.
In the last 2 years, I have been working in the application of Chimeric Antigen Receptor T cell based immunotherapy (CARTs) as a promising advanced therapy for cancer treatment (hematological malignancies as ALL, AML, MM and solid tumors). During this period I have gained a tremendous experience in different experimental approaches (i) isolation of T lymphocytes from blood samples, (ii) generation and expansion of CART cells (iii) phenotypic characterization of CART cells by flow cytometry analyses of specific surface markers (iv) functional characterization (in vitro and in vivo cytotoxicity assays). Since we already have the required CARTs, we are also performing multi-omic technologies (transcriptomic, analyses by single-cell RNA-seq, epigenomic analyses by ChIP-seq and ATAC-seq) that have been implemented in the group in collaboration with the Advanced Genomic Laboratory at CIMA.
I have a total of 12 published articles of which I am first author of 6. I have participated in many national and international congress and workshops with 15 poster contributions and 2 oral presentations in the field of Advanced Therapies and Hemato-oncology.
研究兴趣
论文共 24 篇作者统计合作学者相似作者
按年份排序按引用量排序主题筛选期刊级别筛选合作者筛选合作机构筛选
时间
引用量
主题
期刊级别
合作者
合作机构
FRONTIERS IN IMMUNOLOGY (2023): 1270843-1270843
BLOOD (2023)
Journal for ImmunoTherapy of Cancerno. Suppl 1 (2023)
HUMAN GENE THERAPYno. 19-20 (2021): A37-A38
引用0浏览0引用
0
0
Paula Rodriguez-Marquez,Maria Erendira Calleja-Cervantes,Martin-Uriz Patxi San,Angel Martin-Mallo, Sampedro Cristina Calvino,Sancho Susana Inoges, De Cerio Ascesion Lopez-Diaz,Rebeca Martinez-Turrillas,Saray Rodriguez-Diaz,Paula Rodriguez-Otero,Roca Jose Rifon,Pierola Ana Alfonso,
引用0浏览0引用
0
0
引用0浏览0引用
0
0
加载更多
作者统计
合作学者
合作机构
D-Core
- 合作者
- 学生
- 导师
数据免责声明
页面数据均来自互联网公开来源、合作出版商和通过AI技术自动分析结果,我们不对页面数据的有效性、准确性、正确性、可靠性、完整性和及时性做出任何承诺和保证。若有疑问,可以通过电子邮件方式联系我们:report@aminer.cn